Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 147.98
(1.72%)
INR 147.98
(1.72%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 14.79 Million INR | 135.49% |
| 2022 | -41.68 Million INR | -189354.55% |
| 2021 | -22 Thousand INR | -100.07% |
| 2020 | 33.17 Million INR | 119.73% |
| 2019 | -168.18 Million INR | -315.02% |
| 2018 | 78.21 Million INR | 283.29% |
| 2017 | 20.4 Million INR | -33.46% |
| 2016 | 30.66 Million INR | -53.89% |
| 2015 | 66.51 Million INR | 311.06% |
| 2014 | 16.18 Million INR | -55.94% |
| 2013 | 36.72 Million INR | -8.13% |
| 2012 | 39.97 Million INR | 0.0% |
| 2011 | - INR | 0.0% |
| 2010 | - INR | 0.0% |
| 2009 | - INR | 0.0% |
| 2008 | - INR | 0.0% |
| 2007 | - INR | 0.0% |
| 2006 | - INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 1.00 INR | 0.0% |
| 2023 Q4 | 14.79 Million INR | 0.0% |
| 2023 FY | 14.79 Million INR | 135.49% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | 100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | -41.68 Million INR | -189354.55% |
| 2022 Q4 | -41.68 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 331.75 Million INR | 0.0% |
| 2021 Q2 | 1.00 INR | 0.0% |
| 2021 Q4 | 10.77 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | -22 Thousand INR | -100.07% |
| 2020 FY | 33.17 Million INR | 119.73% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 1.00 INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 7.96 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 24.82 Million INR | 0.0% |
| 2019 FY | -168.18 Million INR | -315.02% |
| 2019 Q2 | 1.00 INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 49.38 Million INR | 0.0% |
| 2018 Q2 | 5.9 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 78.21 Million INR | 283.29% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 20.4 Million INR | -33.46% |
| 2017 Q4 | 20.4 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 8.6 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 30.66 Million INR | 0.0% |
| 2016 FY | 30.66 Million INR | -53.89% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 1.00 INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 66.51 Million INR | 311.06% |
| 2015 Q2 | 1.00 INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 66.51 Million INR | 0.0% |
| 2014 Q4 | 16.18 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 16.18 Million INR | -55.94% |
| 2014 Q2 | 377.5 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 621.5 Million INR | 0.0% |
| 2013 Q4 | 36.72 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 36.72 Million INR | -8.13% |
| 2012 Q4 | 39.97 Million INR | 0.0% |
| 2012 FY | 39.97 Million INR | 0.0% |
| 2011 FY | - INR | 0.0% |
| 2011 Q4 | - INR | 0.0% |
| 2010 FY | - INR | 0.0% |
| 2009 FY | - INR | 0.0% |
| 2008 FY | - INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2006 FY | - INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Hester Biosciences Limited | 755.81 Million INR | 98.043% |
| RPG Life Sciences Limited | 1.01 Billion INR | 98.535% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 99.36% |
| Ipca Laboratories Limited | 24.71 Billion INR | 99.94% |
| Aarti Drugs Limited | 4.85 Billion INR | 99.696% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 99.77% |
| Albert David Limited | 436.12 Million INR | 96.608% |
| Alembic Limited | 113.4 Million INR | 86.956% |
| Alkem Laboratories Limited | 26.61 Billion INR | 99.944% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 99.91% |
| Bafna Pharmaceuticals Limited | 296.41 Million INR | 95.01% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 98.973% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | 41.985% |
| Brooks Laboratories Limited | 96.1 Million INR | 84.609% |
| Eris Lifesciences Limited | 1.89 Billion INR | 99.217% |
| FDC Limited | 3.88 Billion INR | 99.62% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 99.778% |
| Gufic Biosciences Limited | 2 Billion INR | 99.262% |
| Hikal Limited | 3.03 Billion INR | 99.513% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | 85.855% |
| Ind-Swift Limited | 640.91 Million INR | 97.692% |
| Innova Captab Limited | 1.44 Billion INR | 98.973% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 99.652% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | 90.137% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 99.885% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | 62.909% |
| Laurus Labs Limited | 18.45 Billion INR | 99.92% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | 98.083% |
| Lupin Limited | 49.53 Billion INR | 99.97% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 98.804% |
| Medico Remedies Limited | 163.37 Million INR | 90.946% |
| Morepen Laboratories Limited | 2.48 Billion INR | 99.405% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 99.791% |
| Orchid Pharma Limited | 2.64 Billion INR | 99.44% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 98.644% |
| Sigachi Industries Limited | 707.2 Million INR | 97.908% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 99.589% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.985% |
| Themis Medicare Limited | 705.74 Million INR | 97.904% |
| Unichem Laboratories Limited | 7.04 Billion INR | 99.79% |
| Vaishali Pharma Limited | 3.79 Million INR | -289.571% |
| Venus Remedies Limited | 1.21 Billion INR | 98.784% |
| Wanbury Limited | 360.23 Million INR | 95.894% |
| Windlas Biotech Limited | 621.89 Million INR | 97.621% |
| ZIM Laboratories Limited | 812.62 Million INR | 98.18% |
| Sakar Healthcare Limited | 277.32 Million INR | 94.666% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.985% |
| Divi's Laboratories Limited | 31.84 Billion INR | 99.954% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 99.351% |
| Mankind Pharma Limited | 15.53 Billion INR | 99.905% |
| Sequent Scientific Limited | 3.46 Billion INR | 99.573% |
| Neuland Laboratories Limited | 3.5 Billion INR | 99.578% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 99.706% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 99.941% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 99.957% |
| Amrutanjan Health Care Limited | 289.04 Million INR | 94.882% |
| Wockhardt Limited | 6.4 Billion INR | 99.769% |
| Bal Pharma Limited | 878.11 Million INR | 98.315% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.977% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 98.751% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | 64.587% |
| Caplin Point Laboratories Limited | 3.63 Billion INR | 99.593% |
| Shilpa Medicare Limited | 3.44 Billion INR | 99.571% |
| Valiant Laboratories Limited | 100.15 Million INR | 85.231% |
| Ajanta Pharma Limited | 8.28 Billion INR | 99.821% |
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | 95.734% |
| Granules India Limited | 13 Billion INR | 99.886% |
| Medicamen Biotech Limited | 593.75 Million INR | 97.509% |
| Syncom Formulations (India) Limited | 210.81 Million INR | 92.983% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 99.935% |
| NATCO Pharma Limited | 7 Billion INR | 99.789% |
| Suven Life Sciences Limited | 7.08 Million INR | -108.779% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | 84.901% |
| Strides Pharma Science Limited | 11.26 Billion INR | 99.869% |
| Indoco Remedies Limited | 3.53 Billion INR | 99.581% |
| Alpa Laboratories Limited | 136.65 Million INR | 89.176% |
| Lasa Supergenerics Limited | 190.43 Million INR | 92.232% |